Literature DB >> 28609656

Kupffer Cell-Derived Tnf Triggers Cholangiocellular Tumorigenesis through JNK due to Chronic Mitochondrial Dysfunction and ROS.

Detian Yuan1, Shan Huang2, Emanuel Berger3, Lei Liu4, Nina Gross5, Florian Heinzmann6, Marc Ringelhan7, Tracy O Connor1, Mira Stadler2, Michael Meister2, Julia Weber5, Rupert Öllinger5, Nicole Simonavicius8, Florian Reisinger8, Daniel Hartmann4, Rüdiger Meyer9, Maria Reich10, Marco Seehawer6, Valentina Leone8, Bastian Höchst11, Dirk Wohlleber11, Simone Jörs5, Marco Prinz12, Duncan Spalding13, Ulrike Protzer8, Tom Luedde14, Luigi Terracciano15, Matthias Matter15, Thomas Longerich16, Percy Knolle11, Thomas Ried9, Verena Keitel10, Fabian Geisler5, Kristian Unger17, Einat Cinnamon18, Eli Pikarsky19, Norbert Hüser4, Roger J Davis20, Darjus F Tschaharganeh21, Roland Rad5, Achim Weber22, Lars Zender23, Dirk Haller24, Mathias Heikenwalder25.   

Abstract

Intrahepatic cholangiocarcinoma (ICC) is a highly malignant, heterogeneous cancer with poor treatment options. We found that mitochondrial dysfunction and oxidative stress trigger a niche favoring cholangiocellular overgrowth and tumorigenesis. Liver damage, reactive oxygen species (ROS) and paracrine tumor necrosis factor (Tnf) from Kupffer cells caused JNK-mediated cholangiocellular proliferation and oncogenic transformation. Anti-oxidant treatment, Kupffer cell depletion, Tnfr1 deletion, or JNK inhibition reduced cholangiocellular pre-neoplastic lesions. Liver-specific JNK1/2 deletion led to tumor reduction and enhanced survival in Akt/Notch- or p53/Kras-induced ICC models. In human ICC, high Tnf expression near ICC lesions, cholangiocellular JNK-phosphorylation, and ROS accumulation in surrounding hepatocytes are present. Thus, Kupffer cell-derived Tnf favors cholangiocellular proliferation/differentiation and carcinogenesis. Targeting the ROS/Tnf/JNK axis may provide opportunities for ICC therapy.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  JNK; Kupffer cell; Tnf; cholastasis; intrahepatic cholangiocarcinoma; mitochondrial dysfunction; pro-inflammatory niche; reactive oxygen species; unfolded protein response

Mesh:

Substances:

Year:  2017        PMID: 28609656     DOI: 10.1016/j.ccell.2017.05.006

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  55 in total

Review 1.  Reactive Oxygen Species: the Dual Role in Physiological and Pathological Conditions of the Human Body.

Authors:  Sanaa K Bardaweel; Mustafa Gul; Muhammad Alzweiri; Aman Ishaqat; Husam A ALSalamat; Rasha M Bashatwah
Journal:  Eurasian J Med       Date:  2018-10

Review 2.  Hepatocellular carcinoma.

Authors:  Josep M Llovet; Robin Kate Kelley; Augusto Villanueva; Amit G Singal; Eli Pikarsky; Sasan Roayaie; Riccardo Lencioni; Kazuhiko Koike; Jessica Zucman-Rossi; Richard S Finn
Journal:  Nat Rev Dis Primers       Date:  2021-01-21       Impact factor: 52.329

Review 3.  New insights into the role and mechanism of c-Jun-N-terminal kinase signaling in the pathobiology of liver diseases.

Authors:  Sanda Win; Tin Aung Than; Jun Zhang; Christina Oo; Robert Win Maw Min; Neil Kaplowitz
Journal:  Hepatology       Date:  2018-04-06       Impact factor: 17.425

Review 4.  The immunological and metabolic landscape in primary and metastatic liver cancer.

Authors:  Xin Li; Pierluigi Ramadori; Dominik Pfister; Marco Seehawer; Lars Zender; Mathias Heikenwalder
Journal:  Nat Rev Cancer       Date:  2021-07-29       Impact factor: 60.716

Review 5.  From NASH to HCC: current concepts and future challenges.

Authors:  Quentin M Anstee; Helen L Reeves; Elena Kotsiliti; Olivier Govaere; Mathias Heikenwalder
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-07       Impact factor: 46.802

6.  Ecliptasaponin A induces apoptosis through the activation of ASK1/JNK pathway and autophagy in human lung cancer cells.

Authors:  Jia Han; Wang Lv; Hongxu Sheng; Yiqing Wang; Longxiang Cao; Sha Huang; Linhai Zhu; Jian Hu
Journal:  Ann Transl Med       Date:  2019-10

Review 7.  Targeting cancer-promoting inflammation - have anti-inflammatory therapies come of age?

Authors:  Jiajie Hou; Michael Karin; Beicheng Sun
Journal:  Nat Rev Clin Oncol       Date:  2021-01-19       Impact factor: 66.675

Review 8.  Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy.

Authors:  Juan Wang; Sumera Ilyas
Journal:  Expert Opin Investig Drugs       Date:  2020-12-28       Impact factor: 6.206

Review 9.  The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma.

Authors:  Oraianthi Fiste; Ioannis Ntanasis-Stathopoulos; Maria Gavriatopoulou; Michalis Liontos; Konstantinos Koutsoukos; Meletios Athanasios Dimopoulos; Flora Zagouri
Journal:  Vaccines (Basel)       Date:  2021-04-22

Review 10.  Liver Cancer Immunity.

Authors:  Sumera Rizvi; Juan Wang; Anthony B El-Khoueiry
Journal:  Hepatology       Date:  2020-11-07       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.